智通财经APP讯,复星医药(02196)发布公告,近日,本公司收到中国证券监督管理委员会(中国证监会)出具的《关于同意上海复星医药(集团)股份有限公司向专业投资者公开发行科技创新公司债券注册的批复》(证监许可[2026]298号)(批复)。
根据批复,中国证监会同意本公司向专业投资者公开发行面值总额不超过人民币60亿元科技创新公司债券的注册申请。该批复自同意注册之日起24个月内有效,本公司在注册有效期内可分期发行科技创新公司债券。
智通财经APP讯,复星医药(02196)发布公告,近日,本公司收到中国证券监督管理委员会(中国证监会)出具的《关于同意上海复星医药(集团)股份有限公司向专业投资者公开发行科技创新公司债券注册的批复》(证监许可[2026]298号)(批复)。
根据批复,中国证监会同意本公司向专业投资者公开发行面值总额不超过人民币60亿元科技创新公司债券的注册申请。该批复自同意注册之日起24个月内有效,本公司在注册有效期内可分期发行科技创新公司债券。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.